Patents by Inventor Yuya Oguro
Yuya Oguro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240309016Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: March 15, 2024Publication date: September 19, 2024Inventors: Mitsunori KONO, Yusuke SASAKI, Yuya OGURO, Zenichi IKEDA, Osamu KUBO, Masaki SETO, Toru YAMASHITA, Makoto KAMATA, Kenjiro SATO, Matthew Thomas REYNOLDS, Kazuaki TAKAMI, Asato KINA, Takafumi YUKAWA, Minoru NAKAMURA, Taku KAMEI, Hiroyuki KAKEI, Fumie YAMAGUCHI, Tomohiro OHASHI, Keiko KAKEGAWA, Takuto KOJIMA, Florian PÜNNER, Masataka MURAKAMI, Takahiko TANIGUCHI, Tatsuki KOIKE, Yuichi KAJITA, Yuhei MIYANOHANA, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Yasushi HATTORI, Eiji KIMURA, Martin Alexander PAWLICZEK, Marilena PIRA, Shuhei IKEDA, Noriyuki TEZUKA, Yoshikazu WATANABE, Kevin CURRAN, Nicolle DOERING, Maria HOPKINS, Ben JOHNSON, Andre KIRYANOV, Jon LAM, Sean MURPHY, Natasha O'ROURKE, Holly REICHARD, Paul TANIS, Yunlong ZHANG
-
Publication number: 20240217957Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: November 29, 2023Publication date: July 4, 2024Inventors: Asato KINA, Zenichi IKEDA, Mitsunori KONO, Yuya OGURO, Osamu KUBO, Toru YAMASHITA, Kazuaki TAKAMI, Takafumi YUKAWA, Masaki SETO, Makoto KAMATA, Kenjiro SATO, Masataka MURAKAMI, Yusuke SASAKI, Matthew Thomas REYNOLDS, Minoru NAKAMURA, Taku KAMEI, Hiroyuki KAKEI, Fumie YAMAGUCHI, Tomohiro OHASHI, Takuto KOJIMA, Keiko KAKEGAWA, Florian PÜNNER, Shinji NAKAMURA, Nao MORISHITA, Tadashi HIDAKA, Sachie TAKASHIMA, Takahiko TANIGUCHI
-
Patent number: 11952344Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.Type: GrantFiled: September 25, 2020Date of Patent: April 9, 2024Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuya Oguro, Makoto Kamata, Shuhei Ikeda, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Shigemitsu Matsumoto, Hirotaka Kamitani, Takaharu Hirayama, Toshio Tanaka, Hiroshi Banno, Nobuyuki Takakura, Jinichi Yonemori, Takuya Fujimoto
-
Patent number: 11834409Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.Type: GrantFiled: December 22, 2022Date of Patent: December 5, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Shuhei Ikeda, Makoto Kamata, Yuya Oguro, Masataka Murakami, Minoru Nakamura, Fumie Yamaguchi, Takafumi Yukawa
-
Patent number: 11827601Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.Type: GrantFiled: December 22, 2022Date of Patent: November 28, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Shuhei Ikeda, Makoto Kamata, Yuya Oguro
-
Publication number: 20230357220Abstract: Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer’s disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6?-(phenyl)-2H-(1,2?-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).Type: ApplicationFiled: May 20, 2021Publication date: November 9, 2023Inventors: Tomoaki HASUI, Satoshi MIKAMI, JR., Toru YAMASHITA, Shinji NAKAMURA, Shinji MORIMOTO, Toshihiro IMAEDA, Kazuaki TAKAMI, Masaki DAINI, Hiroyuki KAKEI, Minoru NAKAMURA, Fumie YAMAGUCHI, Chunxiang WANG, Sachie TAKASHIMA, Makoto KAMATA, Yuya OGURO, Shuhei IKEDA
-
Patent number: 11746109Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I)·0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.Type: GrantFiled: March 27, 2017Date of Patent: September 5, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Kentaro Iwata, Masahiro Mizuno, Kazuhiro Maeda, Tsuneo Yasuma, Misaki Homma, Yuya Oguro, Naohiro Taya, Lei Zhu, John Daniel Bailey, Marianne Langston, Siddhesh Dinanath Patil, Shruti Gour, Lilly Roy
-
Patent number: 11713311Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: December 14, 2021Date of Patent: August 1, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Eiji Kimura, Masaki Ogino, Yasuhisa Kohara, Tomoko Ohashi, Tomohiro Kaku, Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito
-
Patent number: 11702419Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: GrantFiled: March 15, 2021Date of Patent: July 18, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Satoshi Mikami, Masaki Seto, Shinji Morimoto, Shinji Nakamura, Sachie Takashima, Masataka Murakami, Masaki Daini, Makoto Kamata, Minoru Nakamura, Yasufumi Wada, Hiroyuki Kakei, Kazuaki Takami, Taisuke Tawaraishi, Jumpei Aida, Kouichi Iwanaga, Satoshi Yamamoto
-
Publication number: 20230150934Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.Type: ApplicationFiled: December 22, 2022Publication date: May 18, 2023Inventors: Shuhei IKEDA, Makoto KAMATA, Yuya OGURO, Jumpei AIDA, Taisuke TAWARAISHI, Takeshi WAKABAYASHI, Norio OYABU, Atsuko OCHIDA, Kouichi IWANAGA, Satoshi YAMAMOTO, Masataka MURAKAMI, Minoru NAKAMURA, Fumie YAMAGUCHI, Takafumi YUKAWA
-
Publication number: 20230134307Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.Type: ApplicationFiled: December 22, 2022Publication date: May 4, 2023Inventors: Shuhei IKEDA, Makoto KAMATA, Yuya OGURO, Jumpei AIDA, Taisuke TAWARAISHI, Takeshi WAKABAYASHI, Norio OYABU, Atsuko OCHIDA, Kouichi IWANAGA, Satoshi YAMAMOTO, Masataka MURAKAMI, Minoru NAKAMURA, Fumie YAMAGUCHI, Takafumi YUKAWA
-
Publication number: 20230102273Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I).0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.Type: ApplicationFiled: March 27, 2017Publication date: March 30, 2023Inventors: Kentaro IWATA, Masahiro MIZUNO, Kazuhiro MAEDA, Tsuneo YASUMA, Misaki HOMMA, Yuya OGURO, Naohiro TAYA, Lei ZHU, John Daniel BAILEY, Marianne LANGSTON, Siddhesh Dinanath PATIL, Shruti GOUR, Lilly ROY
-
Publication number: 20230002318Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.Type: ApplicationFiled: November 12, 2020Publication date: January 5, 2023Inventors: Shuhei IKEDA, Makoto KAMATA, Yuya OGURO, Jumpei AIDA, Taisuke TAWARAISHI, Takeshi WAKABAYASHI, Norio OYABU, Atsuko OCHIDA, Kouichi IWANAGA, Satoshi YAMAMOTO, Masataka MURAKAMI, Minoru NAKAMURA, Fumie YAMAGUCHI, Takafumi YUKAWA
-
Publication number: 20220388995Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: December 14, 2021Publication date: December 8, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Eiji KIMURA, Masaki OGINO, Yasuhisa KOHARA, Tomoko OHASHI, Tomohiro KAKU, Yuya OGURO, Shigemitsu MATSUMOTO, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO
-
Publication number: 20220340527Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: September 25, 2020Publication date: October 27, 2022Inventors: Yuya OGURO, Makoto KAMATA, Shuhei IKEDA, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO, Shigemitsu MATSUMOTO, Hirotaka KAMITANI, Takaharu HIRAYAMA, Toshio TANAKA, Hiroshi BANNO, Nobuyuki TAKAKURA, Jinichi YONEMORI, Takuya FUJIMOTO
-
Publication number: 20220089525Abstract: A heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like is provided. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: January 23, 2020Publication date: March 24, 2022Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yuya OGURO, Makoto KAMATA, Satoshi MIKAMI, Shinji MORIMOTO, Sachie TAKASHIMA, Masaki DAINI, Osamu KUBO, Fumiaki KIKUCHI, Akinori TOITA, Florian PUENNER, Takahito KASAHARA, Masataka MURAKAMI, Shuhei IKEDA, Fumie YAMAGUCHI, Minoru NAKAMURA, Takafumi YUKAWA
-
Patent number: 11230541Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: July 26, 2018Date of Patent: January 25, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Eiji Kimura, Masaki Ogino, Yasuhisa Kohara, Tomoko Ohashi, Tomohiro Kaku, Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito
-
Publication number: 20210332053Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: ApplicationFiled: March 15, 2021Publication date: October 28, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuya OGURO, Shigemitsu MATSUMOTO, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO, Satoshi MIKAMI, Masaki SETO, Shinji MORIMOTO, Shinji NAKAMURA, Sachie TAKASHIMA, Masataka MURAKAMI, Masaki DAINI, Makoto KAMATA, Minoru NAKAMURA, Yasufumi WADA, Hiroyuki KAKEI, Kazuaki TAKAMI, Taisuke TAWARAISHI, Jumpei AIDA, Kouichi IWANAGA, Satoshi YAMAMOTO
-
Patent number: 10807987Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: GrantFiled: March 27, 2019Date of Patent: October 20, 2020Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Satoshi Mikami, Masaki Seto, Shinji Morimoto, Shinji Nakamura, Sachie Takashima, Masataka Murakami, Masaki Daini, Makoto Kamata, Minoru Nakamura, Yasufumi Wada, Hiroyuki Kakei, Kazuaki Takami, Taisuke Tawaraishi, Jumpei Aida, Kouichi Iwanaga, Satoshi Yamamoto
-
Publication number: 20200231579Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: July 26, 2018Publication date: July 23, 2020Applicant: Takeda Pharmaceutical Company LimitedInventors: Eiji KIMURA, Masaki OGINO, Yasuhisa KOHARA, Tomoko OHASHI, Tomohiro KAKU, Yuya OGURO, Shigemitsu MATSUMOTO, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO
